All In Biotech

Drug Trial Radar · NCT04488081

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

I-SPY COVID TRIAL: An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients

Last checked: Nov 19, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 1,500 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,500

Planned (sponsor's estimate)

Start

Jul 31, 2020

Primary completion

Jul 31, 2028

Study completion Jul 31, 2030

Sponsor

Lead sponsor
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of California, San Francisco; Emory University; University of Alabama at Birmingham; University of Colorado, Denver; University of Southern California; Yale University; Wake Forest University Health Sciences; Long Beach Memorial Medical Center; Georgetown University; University of California, Davis; Main Line Health; DHR Health Institute for Research and Development; University of California, Irvine; University of Michigan; West Virginia University; University of Miami; University Hospitals Cleveland Medical Center; M.D. Anderson Cancer Center
First posted
Jul 27, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.

Conditions

  • COVID-19

Interventions

  • RemdesivirDrug

    Participants who receive remdesivir as part of their standard of care will be administered remdesivir by IV for up to ten days. Remdesivir 200mg loading dose on day 1, followed by 100mg IV once daily maintenance doses for 4 or 9 days.

  • Imatinib MesylateDrug

    Subjects will be administered 800 mg on Day 1 orally, in divided doses of 400 mg administered twice per day. 400 mg daily will be administered orally for the following 9 days or until discharge, whichever is sooner.

  • DexamethasoneDrug

    6 mg intravenous of oral dexamethasone once daily up to 10 days or equivalent for alternate corticosteroid if dexamethasone unavailable.

  • CenicrivirocDrug

    Oral, loading 300 mg qAM followed by 150 mg qPM, 12 hours apart on day 1, then 150 mg BID for total of 14 to 28 days depending on date of hospital discharge.

  • IcatibantDrug

    Subcutaneous, a safety run-in for the first 10 subjects was conducted using a regimen of 30 mg q8h × 3 days. All subsequent subjects received drug at 30 mg q8h x 6 days.

  • ApremilastDrug

    oral, 30 mg bid × 14 days.

  • dornase alfaBiological

    For Non-intubated subjects: 2.5 mg BID until hospital discharge, improvement to room air (or baseline oxygen use prior to illness) for 24 hours, or total of 14 days of study drug, whichever comes first. For intubated subjects: 5.0 mg BID in 10 mL normal saline until extubation or 14 days, whichever comes first. If intubated for less than 14 days, extubated subjects received 2.5 mg BID for a total Dornase treatment of 14 days, or until hospital discharge, whichever comes first.

  • CelecoxibDrug

    Oral: 400 mg BID for 7 days.

  • FamotidineDrug

    Oral: High dose 80 mg QID for 7 days followed by 40 mg BID for a course of 14 days.

  • IC14Biological

    intravenous, 4 mg/kg on day 1, followed by 2 mg/kg on days 2, 3, 4

  • AviptadilDrug

    Inhalation via nebulizer, 100 µg three times (TID) daily for a maximum of 14 days

  • narsoplimabBiological

    Dosed at 4 mg/kg, given as a 30-minute intravenous infusion (up to a maximum of 370 mg per infusion) twice weekly for a total of four weeks (i.e. 9 doses) or until hospital discharge whichever comes first.

  • CyproheptadineDrug

    4 mg tablet, with dosing regimen of 8 mg every 8 hours daily for ten (10) days. If the patient weighs less than 48 kg, the regimen is 6 mg every 8 hours daily for ten (10) days. If the participant was discharged before completion of this dosing regimen the drug was not continued.

  • CyclosporineDrug

    Modified CsA at an oral dose of 5mg/kg per day administered in two divided doses daily for 5-days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Identify agents that will result in substantial improvements to the clinical condition of participants with COVID-19.Time frame: Up to 28 days

Locations

36 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • UC Davis Medical Center

    Davis, California

  • UC Irvine Medical Center

    Irvine, California

  • Long Beach Memorial Medical Center

    Long Beach, California

  • Kaiser LAMC

    Los Angeles, California

  • University of Southern California

    Los Angeles, California

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California

  • University of California San Francisco (UCSF)

    San Francisco, California

  • University of Colorado

    Aurora, Colorado

  • Yale Cancer Center

    New Haven, Connecticut

  • Stamford Health

    Stamford, Connecticut

  • Georgetown University

    Washington D.C., District of Columbia

  • University of Miami

    Coral Gables, Florida

  • University of Florida

    Gainesville, Florida

  • Emory University

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • University of Iowa

    Iowa City, Iowa

  • University of Michigan

    Ann Arbor, Michigan

  • Corewell Health

    Grand Rapids, Michigan

  • Mercy Hospital Springfield

    Springfield, Missouri

  • Kalispell Regional Medical Center

    Kalispell, Montana

  • Logan Health Medical Center

    Kalispell, Montana

  • Virtua Mount Holly Hospital

    Mount Holly, New Jersey

  • Virtua Voorhees Hospital

    Voorhees Township, New Jersey

  • Columbia University Medical Center

    New York, New York

  • University of Rochester Medical Center

    Rochester, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Wake Forest Baptist Comprehensive Cancer Center

    Winston-Salem, North Carolina

  • University Hospital Cleveland Medical Center

    Cleveland, Ohio

  • University of Pennsylvania (U Penn)

    Philadelphia, Pennsylvania

  • Lankenau Medical Center (Mainline Health)

    Wynnewood, Pennsylvania

  • Main Line Health - Lankenau Medical Center

    Wynnewood, Pennsylvania

  • Sanford Health

    Souix Falls, South Dakota

  • DHR Health

    Edinburg, Texas

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • WVU Medicine

    Morgantown, West Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.